Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 5Terminated 4Unknown 2Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 16OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Neoplastic Cells, Circulating 1Melanoma 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × OTHER × Digoxin × Clear all
NCT01162135 2025-05-04

Digoxin for Recurrent Prostate Cancer

Thomas Jefferson University

Phase 2 Completed
16 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT05507775 2024-04-11

DIGUP-TC

Radboud University Medical Center

Phase NA Completed
8 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03928210 2023-12-13

Digoxin Induced Dissolution of CTC Clusters

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
58 enrolled
Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01763931 2020-01-31

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
6 enrolled 8 charts
Breast

Breast Neoplasms

NCT02138292 2018-05-15

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

University of Texas Southwestern Medical Center

Phase 1 Completed
27 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡